March 20th 2021
Dostarlimab plus niraparib and bevacizumab showcased favorable antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.
February 13th 2021
February 12, 2021 - Enfortumab vedotin elicited the highest response rates observed for any regimen examined in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.
February 12th 2021
February 12, 2021 - Ruxolitinib demonstrated a significantly higher overall response rate compared with best available therapy among adolescent and adult patients with chronic graft-versus-host disease.
January 29th 2021
January 29, 2021 - Nab-paclitaxel proved to be noninferior to docetaxel, having showcased improved progression-free survival, overall survival, and overall response rate in patients with previously treated advanced non–small cell lung cancer.
January 17th 2021
January 17, 2021 - Axitinib plus octreotide LAR failed to demonstrate a significant improvement in progression-free survival (PFS) compared with placebo plus octreotide LAR in patients with advanced G1-2 extra-pancreatic neuroendocrine tumors.
January 6th 2021
A community can be defined by any number of characteristics. In Lonial’s case, he has built a community of physicians who’ve come together to treat patients with multiple myeloma.
December 8th 2020
December 8, 2020 — Pevonedistat in combination with azacitidine improved overall survival and prolonged event-free survival compared with azacitidine monotherapy in patients with higher-risk myelodysplastic syndrome.
December 6th 2020
December 6, 2020 — The antibody-drug conjugate belantamab mafodotin continued to showcase efficacy and tolerability in heavily pretreated patients with relapsed/refractory multiple myeloma, inducing durable responses even in those who had previously received 7 or more lines of therapy.
December 5th 2020
December 5, 2020 - The enriched chimeric antigen receptor T-cell therapy bb21217 improved responses and also prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.
November 7th 2020
A 14-mg dose of lenvatinib showed similar safety to the standard 18-mg dose of the agent, when used in combination with everolimus in the second-line treatment of patients with advanced renal cell carcinoma, but noninferiority could not be confirmed.